ProCE Banner Activity

DUO-O: First-line CT + Bevacizumab ± Durvalumab Followed by Maintenance Bevacizumab ± Durvalumab With or Without Olaparib in Newly Diagnosed Advanced Ovarian Cancer Without Tumor BRCA Mutation

Conference Coverage
Slideset

Maintenance therapy with durvalumab + olaparib + bevacizumab following first-line chemotherapy + durvalumab + bevacizumab significantly prolonged PFS in patients with non-tBRCAm advanced ovarian cancer compared with chemotherapy + bevacizumab and bevacizumab maintenance alone.

Released: June 07, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, GSK, and Merck Sharp & Dohme Corp.

AstraZeneca

GSK

Merck Sharp & Dohme Corp.